Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 25 SEK 2.04% Market Closed
Market Cap: 867.8m SEK

Operating Margin
Orexo AB

-26.9%
Current
-23%
Average
6.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-26.9%
=
Operating Profit
-145.9m
/
Revenue
543.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
SE
Orexo AB
STO:ORX
862.6m SEK
-27%
US
Eli Lilly and Co
NYSE:LLY
971.9B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
509.1B USD
27%
CH
Roche Holding AG
SIX:ROG
252.3B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP
24%
CH
Novartis AG
SIX:NOVN
202.4B CHF
33%
US
Merck & Co Inc
NYSE:MRK
249.5B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
147B USD
29%
No Stocks Found

Orexo AB
Glance View

Market Cap
862.6m SEK
Industry
Pharmaceuticals

Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

ORX Intrinsic Value
35.49 SEK
Undervaluation 30%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-26.9%
=
Operating Profit
-145.9m
/
Revenue
543.4m
What is the Operating Margin of Orexo AB?

Based on Orexo AB's most recent financial statements, the company has Operating Margin of -26.9%.

Back to Top